Mainz Biomed B.V. (MYNZ) Stock Analysis

What Mainz Biomed B.V. does

Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.

Key metrics

ETFs linked to MYNZ

Broad-market and Healthcare sector ETFs an investor holding Mainz Biomed B.V. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MYNZ fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Mainz Biomed B.V.?

Mainz Biomed B.V. trades under the ticker MYNZ on NASDAQ.

Which exchange is MYNZ listed on?

MYNZ is listed on NASDAQ.

What sector does Mainz Biomed B.V. operate in?

Mainz Biomed B.V. is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze MYNZ in a portfolio?

PortView shows MYNZ's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.